C4X says MALT-1 study shows no UGT1A1 liability seen in competitors
C4X Discovery Holdings PLC on Thursday said it has completed its preclinical study showing that its MALT-1 lead compounds are free of UGT1A1 enzyme liability at clinically meaningful doses, unlike... | June 1, 2023